Acute Myelogenous Lymphoma (AML)

First (CR1)/Second (CR2) Remission

BMT302
Phase II Ibrutinib Maintenance After Reduced-Intensity Conditioning & Allogeneic HCT in Acute Leukemia
PI: Rezvani Stanford

BMT342
Phase II/III to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
PI: Johnston Pending

Advanced Disease

BMT343
Phase Ib T-Cell-Depleted Graft + Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
PI: Meyer Pending

BMT346
Phase III Tacrolimus/ Methotrexate vs Cyclophosphamide/ Tacrolimus/ Mycophenolate Mofetil in PBSCT
PI: Rezvani BMTCTN

BMT340
Phase III Donor Grafts Derived From Orca Graft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
PI: Meyer Orca Biosystems

First (CR1) or Higher Remission

BMT339
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS&AL
PI: Lowsky Pending

BMT333_EXP
Phase III Expanded Access Omidubicel in Allogeneic Transplantation in Hematological Malignancies
PI: Rezvani Pending

dUCB

KEY
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu